Evaluation of the Pantheris Atherectomy System

Not Applicable

Completed

Conditions: Peripheral Arterial Disease

Interventions: Device: Pantheris System

Registration Number: NCT01937351

Lead Sponsor: Avinger, Inc.

Brief Summary: A non-randomized, prospective, global clinical trial of the Avinger Pantheris System, an atherectomy device that provides directional visualization and imaging as an adjunct to fluoroscopy to aid removal of plaque in diseased lower extremity arteries.

Detailed Description: The trial will enroll up to 173 subjects diagnosed with peripheral arterial disease of the lower extremities at up to 20 sites (up to 3 international sites), including 133 Intention to Treat subjects and up to 2 additional Roll-In subjects at each site (up to 40 Roll-In subjects total). The primary disease must be located in reference vessel diameters ≥ 2.5 mm and ≤ 7.0 mm. Trial success is focused on safety including rates of major adverse events through 6 months as adjudicated by a Clinical Events Committee. Effectiveness will be evaluated using technical success, defined as the percent of target lesions that have a residual diameter stenosis \<50% post-treatment with the Pantheris device alone as assessed by Angiographic Core Lab.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 162

Inclusion Criteria

Age ≥ 18 years old;
Subject is a candidate for percutaneous intervention for peripheral arterial disease in the legs;
Subject is willing and able to give informed consent;
Documented symptomatic atherosclerotic peripheral arterial disease Rutherford Classification 2-5;
Reference vessel lumen proximal to target lesion ≥ 2.5 mm and ≤ 7.0 mm in diameter by visual estimation;
Subject has de novo target lesion(s) with stenosis >70% by visual estimation distal to the profunda femoral artery. No more than 2 lesions may be treated with the Pantheris device;
Target lesion length ≤ 15 cm (may be two tandem lesions that do not exceed 15cm in total length);
Subject is capable of meeting requirements and be present at the follow-up clinic visits at 30 days and 6 months;
At least one patent tibial run-off vessel at baseline.

Inclusion Criteria for the 24-month follow up:

Completed the 6-month follow-up visit
Re-consented prior to the 24-month follow-up visit

Exclusion Criteria

Subject is pregnant or breast feeding;
Rutherford Class 0 to 1 (asymptomatic and mild claudication);
Rutherford Class 6 (critical limb ischemia);
Moderate to severe calcification of the target lesion;
Acute ischemia and/or acute thrombosis of the Superficial Femoral Artery (SFA)-Popliteal segment;
In-stent restenosis within the target lesion;
Target lesion with any type of stent or graft;
Target lesion in the iliac artery;
Target lesion stenosis <70%;
Subjects with significant (≥70%) occlusive lesions proximal to the target lesion not successfully treated during the index procedure (upstream disease) and prior to treatment of the target lesion;
Endovascular or surgical procedure performed on the index limb less than or equal to 30 days prior to the index procedure;
Planned endovascular or surgical procedure 30 days after the index procedure;
Lesion in the contralateral limb requiring intervention during the index procedure or within 30 days of the index procedure;
Subjects with active systemic infections whether they are being currently treated or not;
Subjects on chronic hemodialysis or creatinine level >2.0mg/dL;
Evidence or history of intracranial or gastrointestinal bleeding, intracranial aneurysm, myocardial infarction or stroke within the past 2 months;
Evidence or history of aneurysmal target vessel within the past 2 months;
History of severe trauma, fracture, major surgery or biopsy of a parenchymal organ within the past 14 days;
Known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated;
Subjects in whom anti-platelet, anticoagulant, or thrombolytic therapy is contraindicated;
History of heparin-induced thrombocytopenia (HIT);
Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000/mm2, known coagulopathy, or International Normalized Ratio (INR) >1.5;
Any thrombolytic therapy within 2 weeks of the index procedure;
Any clinical and/or angiographic complication attributed to the use of another device prior to the insertion of the study device into the subject;
Subjects or their legal guardians who have not or will not sign the Informed Consent;
Subjects who are unwilling or unable to comply with the follow-up study requirements;
Participation in any study of an investigational device, medication, biologic or other agent within 30 days prior to enrollment that is either a cardiovascular study or could, in the judgment of the investigator, affect the results of the study.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Pantheris Treatment Arm	Pantheris System	Intervention: Atherectomy using the Pantheris system.

Primary Outcome Measures

Name	Time	Method
Primary Safety Endpoint	Day 0 through 6 Months	The primary safety endpoint is defined as freedom from a composite of major adverse events (MAE) through 6-Month follow-up as adjudicated by an independent Clinical Events Committee (CEC). Individual MAEs include: 1. Cardiovascular related death 2. Unplanned, major index limb amputation 3. Clinically driven target lesion revascularization (TLR) 4. Myocardial infarction 5. Device related events: 1. Clinically significant perforation 2. Clinically significant dissection 3. Clinically significant embolus 4. Pseudoaneurysm
Primary Effectiveness Endpoint: Technical Success	Day 0	The primary efficacy endpoint of technical success is defined as the percent of target lesions that have a residual diameter stenosis \<50% post the Pantheris device alone, as assessed by an independent Angiographic Core Laboratory.

Secondary Outcome Measures

Name	Time	Method
Secondary Effectiveness Endpoint: ABI	6 Month	Ankle-Brachial Index (ABI) at 6 months. ABI is the ratio of blood pressure in the lower legs to the blood pressure in the arms. ABI between 0.95 and 1.3 is considered normal (free from significant peripheral artery disease).
Secondary Effectiveness Endpoint: Procedural Success	Day 0	Procedural success defined as the percent of target lesions that have residual diameter stenosis \< 30% post-Pantheris and any other adjunctive therapy, determined by independent Angiographic Core Laboratory.
Secondary Safety Endpoint	Day 0 through 6 Months	Freedom from clinically driven Target Vessel Revascularization (TVR) through 6 months, as adjudicated by an independent CEC.
Secondary Effectiveness Endpoint: Quality of Life - 12-Item Short Form Survey (SF-12)	6 Month	Change in Quality of Life measures between Baseline and 6 Months using 12-Item Short Form Survey (SF-12). There are two components of the SF-12: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). Each yields scores from 0 (representing the worst possible debilitation) to 100 (representing no reduction in quality of life).
Secondary Effectiveness Endpoint: Rutherford Classification	6 Month	Rutherford Classification at 6 months. Rutherford Classification is a commonly used clinical means for describing the degree of peripheral artery disease. Rutherford Classifications range from Class 0: asymptomatic, to Class 6: major tissue loss.
Secondary Effectiveness Endpoint: Vascular Quality of Life Questionnaire (VascuQoL)	6 Month	Change in Quality of Life measures between Baseline and 6 months using Vascular Quality of Life Questionnaire (VascuQoL). The VascuQoL is a disease-specific questionnaire developed to assess chronic limb ischemia. VascuQol uses a seven-point scale, with 1 representing the worst score and 7 representing the best score.

Trial Locations

Locations (21): St. Dominic Hospital
🇺🇸
Jackson, Mississippi, United States
Deborah Heart and Lung Center
🇺🇸
Browns Mills, New Jersey, United States
Advocate Christ Hospital and Medical Center
🇺🇸
Oak Lawn, Illinois, United States
St. Joseph's Hospital
🇺🇸
Fort Wayne, Indiana, United States
Arkansas Heart Hospital
🇺🇸
Little Rock, Arkansas, United States
Austin Heart
🇺🇸
Austin, Texas, United States
Cedars Sinai Medical Center/Cardiovascular Research Foundation of Southern California
🇺🇸
West Hollywood, California, United States
Medstar Washington Hospital
🇺🇸
Washington, District of Columbia, United States
Einstein Medical Center
🇺🇸
Philadelphia, Pennsylvania, United States
Alexian Brothers Medical Center, Cardiovascular Associates
🇺🇸
Elk Grove Village, Illinois, United States
St. Bernard's Medical Center
🇺🇸
Jonesboro, Arkansas, United States
University of Nebraska Medical Center
🇺🇸
Omaha, Nebraska, United States
Methodist Hospital
🇺🇸
Memphis, Tennessee, United States
Coastal Vascular and Interventional
🇺🇸
Pensacola, Florida, United States
St. Peters University Hospital
🇺🇸
New Brunswick, New Jersey, United States
Dayton Heart Center/Good Samaritan Hospital
🇺🇸
Dayton, Ohio, United States
Muenster Hospital
🇩🇪
Muenster, Germany
Jobst Vascular Center
🇺🇸
Toledo, Ohio, United States
Detroit Medical Center Cardiovascular Institute Harper-Hutzel Hospital
🇺🇸
Detroit, Michigan, United States
Hatton Institute for Research and Education, Good Samaritan Hospital - Bethesda North
🇺🇸
Cincinnati, Ohio, United States
St. John Hospital and Medical Center
🇺🇸
Detroit, Michigan, United States